# A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

> **NCT05068141** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 79 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** SG001
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05068141
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068141, "A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05068141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*